

Fermin Sanchez-Guijo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5782525/publications.pdf>

Version: 2024-02-01

138
papers

5,210
citations

87888

38
h-index

98798

67
g-index

148
all docs

148
docs citations

148
times ranked

8218
citing authors

#	ARTICLE	IF	CITATIONS
1	External evaluation of population pharmacokinetic models of imatinib in adults diagnosed with chronic myeloid leukaemia. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1913-1924.	2.4	10
2	Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). <i>Annals of Oncology</i> , 2022, 33, 259-275.	1.2	139
3	Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 710.e1-710.e10.	1.2	7
4	Improving hematopoietic engraftment: Potential role of mesenchymal stromal cell-derived extracellular vesicles. <i>Stem Cells</i> , 2021, 39, 26-32.	3.2	13
5	Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice. <i>Blood Cancer Journal</i> , 2021, 11, 16.	6.2	29
6	Endobronchial autologous bone marrowâ€“mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial. <i>ERJ Open Research</i> , 2021, 7, 00773-2020.	2.6	10
7	Human bone marrow mesenchymal stromal cell-derived extracellular vesicles modified by enzymatic exofucosylation prevent acute graft-versus-host disease progression. <i>Cytotherapy</i> , 2021, 23, S25-S26.	0.7	0
8	MSCs from polytrauma patients: preliminary comparative study with MSCs from elective-surgery patients. <i>Stem Cell Research and Therapy</i> , 2021, 12, 451.	5.5	1
9	Efficacy and safety of intramuscular administration of allogeneic adipose tissue derived and expanded mesenchymal stromal cells in diabetic patients with critical limb ischemia with no possibility of revascularization: study protocol for a randomized controlled double-blind phase II clinical trial (The NOMA Trial). <i>Trials</i> , 2021, 22, 595.	1.6	7
10	Long-term efficacy of autologous bone marrow mesenchymal stromal cells for treatment of knee osteoarthritis. <i>Journal of Translational Medicine</i> , 2021, 19, 506.	4.4	7
11	Co-administration of human MSC overexpressing HIF-1 β increases human CD34+ cell engraftment in vivo. <i>Stem Cell Research and Therapy</i> , 2021, 12, 601.	5.5	6
12	Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). <i>Bone Marrow Transplantation</i> , 2020, 55, 283-306.	2.4	128
13	Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Bone Marrow Transplantation</i> , 2020, 55, 681-694.	2.4	39
14	Autologous adipose-derived stem cells for the treatment of complex cryptoglandular perianal fistula: A randomized clinical trial with long-term follow-up. <i>Stem Cells Translational Medicine</i> , 2020, 9, 295-301.	3.3	46
15	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Haematologica</i> , 2020, 105, 297-316.	3.5	230
16	Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1217-1224.	2.8	5
17	Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2237-2244.	2.0	14
18	Measures to Maintain a SARS-CoV-2 Negative Inpatient Hematological Unit in the Midst of the COVID-19 Pandemic. <i>Frontiers in Medicine</i> , 2020, 7, 462.	2.6	1

#	ARTICLE	IF	CITATIONS
19	Phase II multicenter randomized controlled clinical trial on the efficacy of intra-articular injection of autologous bone marrow mesenchymal stem cells with platelet rich plasma for the treatment of knee osteoarthritis. <i>Journal of Translational Medicine</i> , 2020, 18, 356.	4.4	48
20	Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. <i>EClinicalMedicine</i> , 2020, 25, 100454.	7.1	136
21	Spanish Cell Therapy Network (TerCel): 15 years of successful collaborative translational research. <i>Cytotherapy</i> , 2020, 22, 1-5.	0.7	6
22	Inhibition of Xanthine Oxidoreductase Enhances the Potential of Tyrosine Kinase Inhibitors against Chronic Myeloid Leukemia. <i>Antioxidants</i> , 2020, 9, 74.	5.1	5
23	Deciphering Master Gene Regulators and Associated Networks of Human Mesenchymal Stromal Cells. <i>Biomolecules</i> , 2020, 10, 557.	4.0	8
24	Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure. <i>Blood</i> , 2020, 136, 49-50.	1.4	3
25	Targeting the Immune System With Mesenchymal Stromal Cell-Derived Extracellular Vesicles: What Is the Cargo's Mechanism of Action?. <i>Frontiers in Bioengineering and Biotechnology</i> , 2019, 7, 308.	4.1	33
26	Subconjunctival injection of mesenchymal stromal cells protects the cornea in an experimental model of GVHD. <i>Ocular Surface</i> , 2019, 17, 285-294.	4.4	36
27	Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus. <i>Frontiers in Immunology</i> , 2019, 10, 1151.	4.8	52
28	Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity. <i>British Journal of Haematology</i> , 2019, 187, 93-104.	2.5	12
29	The Incorporation of Extracellular Vesicles from Mesenchymal Stromal Cells Into CD34+ Cells Increases Their Clonogenic Capacity and Bone Marrow Lodging Ability. <i>Stem Cells</i> , 2019, 37, 1357-1368.	3.2	14
30	Splice donor site sgRNAs enhance CRISPR/Cas9-mediated knockout efficiency. <i>PLoS ONE</i> , 2019, 14, e0216674.	2.5	19
31	Vitamin D Modifies the Incidence of Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation Depending on the Vitamin D Receptor (VDR) Polymorphisms. <i>Clinical Cancer Research</i> , 2019, 25, 4616-4623.	7.0	13
32	Autologous mesenchymal stromal cells embedded in tricalcium phosphate for posterolateral spinal fusion: results of a prospective phase I/II clinical trial with long-term follow-up. <i>Stem Cell Research and Therapy</i> , 2019, 10, 63.	5.5	37
33	SHP1 and SHP2 inhibition enhances the pro-differentiative effect of phorbol esters: an alternative approach against acute myeloid leukemia. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 80.	8.6	11
34	Immediate Effects of Dasatinib on the Migration and Redistribution of Na ⁺ -ve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients. <i>Frontiers in Pharmacology</i> , 2019, 10, 1340.	3.5	11
35	Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 757-761.	2.4	27
36	Clinical Validation of the Myelofibrosis Transplant Scoring System in an Independent Series of Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Transplantation. <i>Blood</i> , 2019, 134, 5733-5733.	1.4	2

#	ARTICLE	IF	CITATIONS
37	Mesenchymal Stromal Cells for Graft-Versus-Host Disease. <i>Stem Cells in Clinical Applications</i> , 2019, , 77-88.	0.4	0
38	Enestpath Leukemic Stem Cell (LSC) Sub-Study: Analyzing Characteristics of LSC-Positive Patients and Impact of Switch from Imatinib to Nilotinib Therapy on LSCs in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2019, 134, 4160-4160.	1.4	0
39	Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Effect of a One-Year Consolidation Treatment with Ponatinib 15 Mg on Treatment Free-Remission Rate in Patients with Philadelphia-Positive Chronic Myeloid Leukemia, Who Had Previously Achieved a Deep Molecular Response with Imatinib (PonaZero study). <i>Blood</i> , 2019, 134, 5904-5904.	1.4	0
40	Biocompatibility of two model elastin-like recombinamer-based hydrogels formed through physical or chemical crosslinking for various applications in tissue engineering and regenerative medicine. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2018, 12, e1450-e1460.	2.7	32
41	Mesenchymal Stromal Cell Irradiation Interferes with the Adipogenic/Osteogenic Differentiation Balance and Improves Their Hematopoietic-Supporting Ability. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 443-451.	2.0	16
42	Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients. <i>Blood Cancer Journal</i> , 2018, 8, 91.	6.2	38
43	Extracorporeal Photopheresis (ECP) for Acute and Chronic Graft versus Host Disease (GVHD): A Retrospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S309.	0.4	0
44	Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?. <i>Annals of Hematology</i> , 2018, 97, 2089-2098.	1.8	18
45	Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: long-term follow up of a multicenter randomized controlled clinical trial (phase I/II). <i>Journal of Translational Medicine</i> , 2018, 16, 213.	4.4	97
46	Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2365-2370.	2.0	61
47	Sequential intravenous allogeneic mesenchymal stromal cells as a potential treatment for thromboangiitis obliterans (Buerger's disease). <i>Stem Cell Research and Therapy</i> , 2018, 9, 150.	5.5	10
48	Second-line treatment for acute graft-versus-host disease with mesenchymal stromal cells: A decision model. <i>European Journal of Haematology</i> , 2018, 101, 676-683.	2.2	4
49	Human Bone Marrow Mesenchymal Stromal Cells Promote Bone Regeneration in a Xenogeneic Rabbit Model: A Preclinical Study. <i>Stem Cells International</i> , 2018, 2018, 1-10.	2.5	11
50	Feasibility of Treatment Discontinuation in Chronic Myeloid Leukemia in Clinical Practice in Spain: Results from a Nationwide Series of 236 Patients. <i>Blood</i> , 2018, 132, 47-47.	1.4	1
51	Senescent Mesenchymal Stem Cells Present at the Early Post Allogeneic Hematopoietic Stem Cell Transplantation Period Are Associated with an Increased Incidence of Acute Graft-Versus Host Disease and Increased Plasma Levels of Fas Ligand. <i>Blood</i> , 2018, 132, 2116-2116.	1.4	0
52	Iron Overload Increases Oxidative Stress and Decreases Clonogenic Capacity of Cells in MDS Patients: Can be Restored after Deferasirox Treatment?. <i>Leukemia Research</i> , 2017, 55, S161-S162.	0.8	0
53	Results of a prospective phase II trial with ofatumumab as part of reduced intensity conditioning regimen in high-risk non-Hodgkin B lymphoma patients: A GELTAMO trial. <i>Hematological Oncology</i> , 2017, 35, 346-347.	1.7	0
54	Regeneration of hyaline cartilage promoted by xenogeneic mesenchymal stromal cells embedded within elastin-like recombinamer-based bioactive hydrogels. <i>Journal of Materials Science: Materials in Medicine</i> , 2017, 28, 115.	3.6	27

#	ARTICLE	IF	CITATIONS
55	Assessment of dry eye in a GVHD murine model: Approximation through tear osmolarity measurement. <i>Experimental Eye Research</i> , 2017, 154, 64-69.	2.6	11
56	Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response. <i>Annals of Hematology</i> , 2017, 96, 81-85.	1.8	28
57	Second-Line Treatment for Steroid-Refractory Graft-Versus-Host Disease with Mesenchymal Stromal Cells. A Conceptual Disease Model. <i>Value in Health</i> , 2017, 20, A545-A546.	0.3	0
58	HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?. <i>Oncotarget</i> , 2017, 8, 28187-28202.	1.8	8
59	Mesenchymal stromal cells (MSC) from JAK2+ myeloproliferative neoplasms differ from normal MSC and contribute to the maintenance of neoplastic hematopoiesis. <i>PLoS ONE</i> , 2017, 12, e0182470.	2.5	19
60	Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients. <i>PLoS ONE</i> , 2016, 11, e0146722.	2.5	70
61	Immunomodulatory effects of bone marrow versus adipose tissue-derived mesenchymal stromal cells on <sc>NK</sc> cells: implications in the transplantation setting. <i>European Journal of Haematology</i> , 2016, 97, 528-537.	2.2	38
62	Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial. <i>Clinical Cancer Research</i> , 2016, 22, 5673-5681.	7.0	39
63	S�ndromes mieloproliferativos. <i>Medicine</i> , 2016, 12, 1213-1223.	0.0	0
64	Cardiovascular management of patients with chronic myeloid leukemia from a multidisciplinary perspective, and proposing action protocol by consensus meeting. <i>Medicina Cl�nica (English Edition)</i> , 2016, 146, 561.e1-561.e8.	0.2	2
65	Insights into the human mesenchymal stromal/stem cell identity through integrative transcriptomic profiling. <i>BMC Genomics</i> , 2016, 17, 944.	2.8	55
66	Comparative analysis of the immunomodulatory capacities of human bone marrow- and adipose tissue-derived mesenchymal stromal cells from the same donor. <i>Cytotherapy</i> , 2016, 18, 1297-1311.	0.7	73
67	Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled clinical trial (phase I/II). <i>Journal of Translational Medicine</i> , 2016, 14, 246.	4.4	238
68	GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study. <i>Bone Marrow Transplantation</i> , 2016, 51, 1524-1526.	2.4	6
69	MSC surface markers (CD44, CD73, and CD90) can identify human MSC-derived extracellular vesicles by conventional flow cytometry. <i>Cell Communication and Signaling</i> , 2016, 14, 2.	6.5	221
70	Extracellular Vesicles Play an Important Role in Intercellular Communication Between Bone Marrow Stroma and Hematopoietic Progenitor Cells in Myeloproliferative Neoplasms. <i>Blood</i> , 2016, 128, 1957-1957.	1.4	3
71	Safety and Efficacy of Dasatinib Treatment Change for Patients Previously Treated with Imatinib with Late Warning Response. Results from the Phase II, Open, Multicenter Dasapost Study. <i>Blood</i> , 2016, 128, 5450-5450.	1.4	1
72	Do endothelial cells belong to the primitive stem leukemic clone in CML? Role of extracellular vesicles. <i>Leukemia Research</i> , 2015, 39, 921-924.	0.8	12

#	ARTICLE	IF	CITATIONS
73	Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodysplastic syndrome. <i>Leukemia Research</i> , 2015, 39, 828-834.	0.8	41
74	Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction. <i>Leukemia Research</i> , 2015, 39, 296-306.	0.8	50
75	Incidence and risk factors for life-threatening bleeding after allogeneic stem cell transplant. <i>British Journal of Haematology</i> , 2015, 169, 719-725.	2.5	37
76	PTPN13 and β -Catenin Regulate the Quiescence of Hematopoietic Stem Cells and Their Interaction with the Bone Marrow Niche. <i>Stem Cell Reports</i> , 2015, 5, 516-531.	4.8	15
77	Efficacy and Safety of Dasatinib in Late Suboptimal Response CML Patients a Its Relation with Lymphocytosis, Lymphocyte Migration and Chemokine Receptor Expression. <i>Blood</i> , 2015, 126, 4015-4015.	1.4	0
78	Transcriptomic portrait of human Mesenchymal Stromal/Stem cells isolated from bone marrow and placenta. <i>BMC Genomics</i> , 2014, 15, 910.	2.8	59
79	Late differentiation syndrome in acute promyelocytic leukemia: a challenging diagnosis. <i>Hematology Reports</i> , 2014, 6, 5654.	0.8	4
80	Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Leukemia Research</i> , 2014, 38, 551-556.	0.8	11
81	Involvement of primary mesenchymal precursors and hematopoietic bone marrow cells from chronic myeloid leukemia patients by <i>BCR-ABL1</i> fusion gene. <i>American Journal of Hematology</i> , 2014, 89, 288-294.	4.1	8
82	Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus. <i>Bone Marrow Transplantation</i> , 2014, 49, 684-690.	2.4	46
83	Sequential Third-Party Mesenchymal Stromal Cell Therapy for Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1580-1585.	2.0	99
84	Elderly CML patients' treatment: Considering not only physician's judgment but also co-morbidity indexes. <i>Leukemia Research</i> , 2014, 38, 1156-1157.	0.8	0
85	NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia. <i>Clinical Cancer Research</i> , 2014, 20, 4014-4025.	7.0	42
86	Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease. <i>Oncotarget</i> , 2014, 5, 8284-8305.	1.8	43
87	Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics. <i>World Journal of Stem Cells</i> , 2014, 6, 322.	2.8	36
88	Uptake and delivery of antigens by mesenchymal stromal cells. <i>Cytotherapy</i> , 2013, 15, 673-678.	0.7	16
89	Unrelated Cord Blood Transplantation. <i>Transplantation</i> , 2013, 95, 1284-1291.	1.0	66
90	Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients. <i>Haematologica</i> , 2013, 98, 437-443.	3.5	69

#	ARTICLE	IF	CITATIONS
91	Effects of MSC Coadministration and Route of Delivery on Cord Blood Hematopoietic Stem Cell Engraftment. <i>Cell Transplantation</i> , 2013, 22, 1171-1183.	2.5	47
92	Bone Marrow Mesenchymal Stem Cell (BM-MSC) Release Microvesicles/Exosomes That Incorporate Into Hematopoietic Cells From MDS Patients and May Modify Their Behaviour. <i>Blood</i> , 2013, 122, 863-863.	1.4	71
93	Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients. <i>Haematologica</i> , 2012, 97, 1218-1224.	3.5	83
94	Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects. <i>PLoS ONE</i> , 2012, 7, e34914.	2.5	61
95	Bone Marrow Transplantation Extends Its Scope. <i>Advances in Experimental Medicine and Biology</i> , 2012, 741, 121-134.	1.6	5
96	Allogeneic mesenchymal stem cell therapy for refractory cytopenias after hematopoietic stem cell transplantation. <i>Transfusion</i> , 2012, 52, 1086-1091.	1.6	20
97	Optimisation of mesenchymal stromal cells karyotyping analysis: implications for clinical use. <i>Transfusion Medicine</i> , 2012, 22, 122-127.	1.1	11
98	Bone Marrow Mesenchymal Stem Cells for Improving Hematopoietic Function: An In Vitro and In Vivo Model. Part 2: Effect on Bone Marrow Microenvironment. <i>PLoS ONE</i> , 2011, 6, e26241.	2.5	38
99	Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial. <i>Haematologica</i> , 2011, 96, 1072-1076.	3.5	155
100	Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study. <i>Leukemia Research</i> , 2011, 35, 1184-1187.	0.8	23
101	Titanium and tantalum as mesenchymal stem cell scaffolds for spinal fusion: an in vitro comparative study. <i>European Spine Journal</i> , 2011, 20, 353-360.	2.2	34
102	Ischemic stroke associated with the infusion of DMSO-cryopreserved auto-PBSCs. <i>Bone Marrow Transplantation</i> , 2011, 46, 1035-1036.	2.4	9
103	Effect of vitamin D treatment in chronic GVHD. <i>Bone Marrow Transplantation</i> , 2011, 46, 1395-1397.	2.4	21
104	Isolation and Characterization of Mesenchymal Stromal Cells From Human Degenerated Nucleus Pulposus. <i>Spine</i> , 2010, 35, 2259-2265.	2.0	178
105	Both CD133 ⁺ Cells and Monocytes Provide Significant Improvement for Hindlimb Ischemia, Although They do not Transdifferentiate Into Endothelial Cells. <i>Cell Transplantation</i> , 2010, 19, 103-112.	2.5	17
106	Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant. <i>American Journal of Hematology</i> , 2010, 85, 290-293.	4.1	2
107	Multiparametric comparison of mesenchymal stromal cells obtained from trabecular bone by using a novel isolation method with those obtained by iliac crest aspiration from the same subjects. <i>Cell and Tissue Research</i> , 2009, 336, 501-507.	2.9	31
108	C013 Genomic aberrations observed in mesenchymal stem cells from 5q-syndrome could be involved in the pathophysiology of the disease. <i>Leukemia Research</i> , 2009, 33, S38-S39.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5qâ syndrome. <i>Leukemia</i> , 2009, 23, 664-672.	7.2	124
110	Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. <i>Leukemia</i> , 2009, 23, 1515-1527.	7.2	122
111	Effects of imatinib mesylate on normal bone marrow cells from chronic myeloid leukemia patients in complete cytogenetic response. <i>Leukemia Research</i> , 2009, 33, 170-173.	0.8	2
112	Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia. <i>Leukemia Research</i> , 2009, 33, e20-e22.	0.8	5
113	Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1331-1336.	2.0	13
114	Prospective comparative analysis of the angiogenic capacity of monocytes and CD133+ cells in a murine model of hind limb ischemia. <i>Cytotherapy</i> , 2009, 11, 1041-1051.	0.7	7
115	Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population. <i>Haematologica</i> , 2009, 94, 975-983.	3.5	51
116	Emergency Surgery of the Abdominal Aorta in a Porcine Model: Two Sequential Experiments. <i>World Journal of Surgery</i> , 2008, 32, 642-647.	1.6	2
117	Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification. <i>Experimental Hematology</i> , 2008, 36, 1014-1021.	0.4	143
118	Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health Scale Plus the Type of Onset Can Predict Survival Rates and the Duration of Immunosuppressive Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1163-1171.	2.0	85
119	Beclometasone dipropionate: a topically active corticosteroid for the treatment of gastrointestinal graft-versus-host disease. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1389-1401.	4.1	3
120	The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. <i>Haematologica</i> , 2008, 93, 1301-1309.	3.5	243
121	Launching a clinical program of stem cell therapy for cardiovascular repair. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, S123-S129.	3.3	4
122	In leukapheresis products from non-Hodgkinâ™s lymphoma patients, the immature hematopoietic progenitors show higher CD90 and CD34 antigenic expression. <i>Transfusion and Apheresis Science</i> , 2007, 37, 145-156.	1.0	4
123	Peripheral endothelial progenitor cells (CD133+) for therapeutic vasculogenesis in a patient with critical limb ischemia. One year follow-up. <i>Cytotherapy</i> , 2007, 9, 99-102.	0.7	30
124	Short-term endothelial progenitor cell colonies are composed of monocytes and do not acquire endothelial markers. <i>Cytotherapy</i> , 2007, 9, 14-22.	0.7	26
125	Alteration of Marrow Cell Gene Expression, Protein Production, and Engraftment into Lung by Lung-Derived Microvesicles: A Novel Mechanism for Phenotype Modulation. <i>Stem Cells</i> , 2007, 25, 2245-2256.	3.2	169
126	Stem cell continuum: Directed differentiation hotspots. <i>Experimental Hematology</i> , 2007, 35, 96-107.	0.4	36

#	ARTICLE	IF	CITATIONS
127	Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Acute Graft-versus-Host Disease (GVHD). <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 936-941.	2.0	36
128	Complete remission of subcutaneous panniculitic T-cell lymphoma after allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2006, 38, 821-822.	2.4	15
129	Posttransplant hematopoiesis in patients undergoing sibling allogeneic stem cell transplantation reflects that of their respective donors although with a lower functional capability. <i>Experimental Hematology</i> , 2005, 33, 935-943.	0.4	10
130	Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. <i>American Journal of Hematology</i> , 2005, 78, 302-305.	4.1	66
131	CD34 ⁺ cell dose and outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2005, 46, 177-183.	1.3	24
132	Long-term Immune Recovery of Patients Undergoing Allogeneic Stem Cell Transplantation: A Comparison with Their Respective Sibling Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 354-361.	2.0	13
133	Endothelial Progenitor Cells (EPC) with Colony Forming Capacity Are Derived from the Monocytic-Macrophage Lineage. <i>Blood</i> , 2005, 106, 4228-4228.	1.4	0
134	Long-term bone marrow culture data are the most powerful predictor of peripheral blood progenitor cell mobilization in healthy donors. <i>Haematologica</i> , 2005, 90, 353-9.	3.5	10
135	Analysis of hematopoietic progenitor cells in patients with myelodysplastic syndromes according to their cytogenetic abnormalities. <i>Leukemia Research</i> , 2004, 28, 1181-1187.	0.8	8
136	Immunophenotypic analysis of Waldenstrom's macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 187-195.	2.2	165
137	Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	24
138	Mesenchymal Stromal Cells Combined With Elastin-Like Recombinamers Increase Angiogenesis In Vivo After Hindlimb Ischemia. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	4.1	3